Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:LXRX NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$8.41-0.7%$9.03$6.00▼$11.23$2.15B0.574.65 million shs2.50 million shsCLDXCelldex Therapeutics$28.62-4.4%$32.00$19.52▼$35.79$2.35B0.95721,094 shs1.27 million shsLXRXLexicon Pharmaceuticals$1.91+0.5%$1.88$0.64▼$2.53$843.97M1.073.10 million shs1.76 million shsNVAXNovavax$9.49-6.9%$8.92$6.13▼$11.97$1.68B2.455.74 million shs4.57 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+2.95%-6.67%-5.95%+0.15%-23.07%CLDXCelldex Therapeutics+0.62%-5.58%-11.61%+1.70%+52.16%LXRXLexicon Pharmaceuticals+2.70%-14.03%+15.15%+11.11%+187.40%NVAXNovavax-0.10%-1.26%+25.93%+2.10%+42.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$8.41-0.7%$9.03$6.00▼$11.23$2.15B0.574.65 million shs2.50 million shsCLDXCelldex Therapeutics$28.62-4.4%$32.00$19.52▼$35.79$2.35B0.95721,094 shs1.27 million shsLXRXLexicon Pharmaceuticals$1.91+0.5%$1.88$0.64▼$2.53$843.97M1.073.10 million shs1.76 million shsNVAXNovavax$9.49-6.9%$8.92$6.13▼$11.97$1.68B2.455.74 million shs4.57 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+2.95%-6.67%-5.95%+0.15%-23.07%CLDXCelldex Therapeutics+0.62%-5.58%-11.61%+1.70%+52.16%LXRXLexicon Pharmaceuticals+2.70%-14.03%+15.15%+11.11%+187.40%NVAXNovavax-0.10%-1.26%+25.93%+2.10%+42.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$20.70146.14% UpsideCLDXCelldex Therapeutics 2.80Moderate Buy$49.7873.93% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.55138.22% UpsideNVAXNovavax 2.10Hold$12.1327.77% UpsideCurrent Analyst Ratings BreakdownLatest LXRX, CLDX, BCRX, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026BCRXBioCryst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/13/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $54.005/11/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.30 ➝ $3.105/8/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $48.005/7/2026NVAXNovavax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/7/2026BCRXBioCryst Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$25.00 ➝ $28.005/7/2026BCRXBioCryst Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$22.00 ➝ $21.005/6/2026BCRXBioCryst Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.005/6/2026NVAXNovavax TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$8.00 ➝ $9.004/20/2026CLDXCelldex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Overweight$24.00 ➝ $45.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.44$1.23 per share6.84($0.57) per share-14.75CLDXCelldex Therapeutics$1.54M1,458.69N/AN/A$7.93 per share3.61LXRXLexicon Pharmaceuticals$49.80M17.04N/AN/A$0.30 per share6.37NVAXNovavax$1.12B1.39$3.27 per share2.90($0.79) per share-12.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A26.28N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)NVAXNovavax$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)Latest LXRX, CLDX, BCRX, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million3/5/2026Q4 2025LXRXLexicon Pharmaceuticals-$0.07-$0.04+$0.03-$0.04$3.14 million$5.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92LXRXLexicon Pharmaceuticals0.2418.8018.77NVAXNovavaxN/A2.482.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/ALXRXLexicon Pharmaceuticals74.70%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals3.80%CLDXCelldex Therapeutics5.20%LXRXLexicon Pharmaceuticals14.00%NVAXNovavax1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableNVAXNovavax1,990164.44 million161.81 millionOptionableLXRX, CLDX, BCRX, and NVAX HeadlinesRecent News About These CompaniesNovavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?3 hours ago | finance.yahoo.comNovavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?June 5 at 12:35 PM | zacks.comNovavax’s Combo COVID-19 and Flu Shot Trial Reaches Key Milestone for Older AdultsJune 5 at 12:31 PM | tipranks.com3 Cash-Burning Stocks We Think Twice AboutJune 4 at 3:44 PM | finance.yahoo.comNovavax, Inc. (NVAX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 4 at 2:03 PM | seekingalpha.comNovavax, Inc. (NASDAQ:NVAX) Receives Average Rating of "Hold" from BrokeragesJune 3 at 2:04 AM | americanbankingnews.comNovavax Inc. stock underperforms Monday when compared to competitorsJune 1, 2026 | marketwatch.comNovavax to Participate in 2026 Jefferies Global Healthcare ConferenceJune 1, 2026 | finance.yahoo.comNovavax to Participate in 2026 Jefferies Global Healthcare ConferenceJune 1, 2026 | prnewswire.comWall Street Zen Upgrades Novavax (NASDAQ:NVAX) to HoldMay 31, 2026 | americanbankingnews.comNovavax: The Pivot To A Royalty Model Is Working, But It's Still A HoldMay 30, 2026 | seekingalpha.comWhy Novavax (NVAX) Stock Is Trading Up TodayMay 26, 2026 | finance.yahoo.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItMay 26, 2026 | finance.yahoo.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItMay 26, 2026 | zacks.com3 Reasons NVAX is Risky and 1 Stock to Buy InsteadMay 25, 2026 | finance.yahoo.comZacks Research Issues Negative Outlook for Novavax EarningsMay 25, 2026 | americanbankingnews.comNovavax Updates Pediatric COVID-19 Vaccine Trial: What Investors Should WatchMay 22, 2026 | tipranks.com3 Small-Cap Stocks That Fall ShortMay 18, 2026 | finance.yahoo.comAssessing Novavax (NVAX) Valuation As Trading Swings Revive Investor InterestMay 18, 2026 | finance.yahoo.comGoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To KnowMay 17, 2026 | finance.yahoo.comVanguard Group Inc. Has $103.96 Million Position in Novavax, Inc. $NVAXMay 13, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXRX, CLDX, BCRX, and NVAX Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$8.41 -0.06 (-0.71%) Closing price 04:00 PM EasternExtended Trading$8.28 -0.13 (-1.59%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$28.62 -1.31 (-4.38%) Closing price 04:00 PM EasternExtended Trading$28.56 -0.06 (-0.21%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Lexicon Pharmaceuticals NASDAQ:LXRX$1.91 +0.01 (+0.53%) Closing price 04:00 PM EasternExtended Trading$1.90 -0.01 (-0.79%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Novavax NASDAQ:NVAX$9.49 -0.70 (-6.87%) Closing price 04:00 PM EasternExtended Trading$9.39 -0.10 (-1.10%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
